Calcineurin抑制劑市場：按藥物類型、按給藥途徑、按適應症、按分銷管道、按最終用戶、按地區

Calcineurin Inhibitor Market, By Drug Type, By Route of Administration, By Indication, By Distribution Channel, By End User, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Calcineurin酶抑制劑市場規模預計在 2025 年為 123.7 億美元，預計到 2032 年將達到 253.6 億美元，2025 年至 2032 年的年複合成長率為 10.8%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	123.7億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	10.80%	2032年價值預測	253.6億美元

Calcineurin抑制劑是一種免疫抑制劑。這些藥物透過抑制免疫系統活動來防止免疫系統攻擊移植器官。它們常用於器官移植，尤其是腎臟、心臟和肝臟移植。Calcineurin抑制劑主要有兩種類型：Cyclosporine和Tacrolimus。這兩種藥物都已被證明能有效防止器官排斥，但也可能伴隨嚴重的副作用，如腎臟損傷、高血壓以及增加感染疾病和癌症的風險。由於器官移植和自體免疫疾病的日益流行，全球Calcineurin抑制劑市場預計將成長。新藥的開發和現有藥物適應症的擴大也在推動市場的發展。然而，這些藥物的副作用和移植的高成本可能會阻礙市場的成長。全球Calcineurin抑制劑市場的主要企業是諾華公司、Astellas製藥、艾爾建和輝瑞。這些公司專注於研發新型改良型Calcineurin酶抑制劑。按地區分類，北美佔據鈣Calcineurin抑制劑市場最大佔有率，其次是歐洲，原因是這些地區器官移植和自體免疫疾病的發生率較高。亞太地區市場預計將出現顯著成長，這得益於該地區醫療支出的增加以及人們對器官移植的認知不斷提高。

市場動態：

預計在不久的將來，自體免疫疾病和器官移植病例的增加將推動全球Calcineurin抑制劑市場的成長。用於預防移植器官排斥反應的Calcineurin抑制劑需求的不斷成長是主要促進因素。Tacrolimus是一種Calcineurin抑制劑，一種用於治療器官移植患者的免疫抑制劑，可降低人體對移植器官的排斥能力。

然而，Calcineurin抑制劑的副作用，例如皮膚刺激和胃腸道疾病，可能會阻礙市場的成長。此外，口服藥物過量相關的風險，例如腎毒性和肝毒性，預計也將在不久的將來阻礙市場的成長。

本研究的主要特點

本報告對全球Calcineurin抑制劑市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球Calcineurin酶抑制劑市場的主要企業概況。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球Calcineurin酶抑制劑市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
可以透過用於分析全球Calcineurin酶抑制劑市場的各種策略矩陣來促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 12.37 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.80%	2032 Value Projection:	USD 25.36 Bn

Calcineurin inhibitors are a type of immunosuppressant. These drugs work by suppressing the activity of the immune system to prevent it from attacking the transplanted organ. They are commonly used in organ transplantation, especially kidney, heart, and liver transplants. There are two main types of calcineurin inhibitors: cyclosporine and tacrolimus. Both of these drugs have been proven to be effective in preventing organ rejection, but they can also have serious side effects, including kidney damage, high blood pressure, and an increased risk of infections and cancer. The global calcineurin inhibitors market is expected to grow due to the increasing prevalence of organ transplantation and autoimmune diseases. The market is also driven by the development of new drugs and the expansion of indications for existing drugs. However, the market growth may be hindered by the side effects of these drugs and the high cost of transplantation. Key players in the global calcineurin inhibitors market include Novartis AG, Astellas Pharma Inc., Allergan, Inc., and Pfizer Inc. These companies are focusing on research and development activities to develop new and improved calcineurin inhibitors. In terms of geography, North America holds the largest share of the calcineurin inhibitors market, followed by Europe. This is due to the high prevalence of organ transplantation and autoimmune diseases in these regions. The market in Asia Pacific is expected to grow at a significant rate due to the increasing healthcare expenditure and the growing awareness about organ transplantation in this region.

Market Dynamics:

Increasing cases of autoimmune diseases and organ transplantation is expected to drive growth of the global calcineurin inhibitor market in the near future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body's ability to reject a transplanted organ.

However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to hamper the market growth in the near future.

Key features of the study:

This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcineurin inhibitor market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market

Detailed Segmentation:

Global Calcineurin Inhibitor Market, By Drug Type:
- Cyclosporine
- Tacrolimus
- Pimecrolimus
- Voclosporin
- Others
Global Calcineurin Inhibitor Market, By Route of Administration:
- Oral
- Topical
- Intravenous
Global Calcineurin Inhibitor Market, By Indication:
- Organ Transplant Rejection Prevention
- Autoimmune Diseases
- Ophthalmic Diseases
- Other Dermatological Conditions
Global Calcineurin Inhibitor Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Calcineurin Inhibitor Market, By End User:
- Hospitals
- Specialty Clinics
- Dermatology Centers
- Transplant Centers
Global Calcineurin Inhibitor Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Novartis AG
- Amgen
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Incyte Corporation
- Chiesi Farmaceutici S.p.A.
- Astellas Pharma Inc.
- Sanofi SA
- Bristol Myers Squibb Company
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd.
- Senju Pharmaceutical Co. Ltd
- Abbott
- Lupin Limited
- Vibcare Pharma Pvt. Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Calcineurin Inhibitor, By Drug Type
- Market Calcineurin Inhibitor, By Route of Administration
- Market Calcineurin Inhibitor, By Indication
- Market Calcineurin Inhibitor, By Distribution Channel
- Market Calcineurin Inhibitor, By End User
- Market Calcineurin Inhibitor, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Calcineurin Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Calcineurin Inhibitor Market, By Drug Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2025 - 2032
- Segment Trends
Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Pimecrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Voclosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Calcineurin Inhibitor Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Calcineurin Inhibitor Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Organ Transplant Rejection Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Other Dermatological Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Calcineurin Inhibitor Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Calcineurin Inhibitor Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Dermatology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Transplant Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

10. Global Calcineurin Inhibitor Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Chiesi Farmaceutici S.p.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Senju Pharmaceutical Co. Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vibcare Pharma Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views